Trial Profile
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progressionon Osimertinib
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Dacomitinib (Primary) ; Osimertinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Jul 2023 Status changed from active, no longer recruiting to completed.
- 23 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 29 Aug 2022 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.